89bio, a San Francisco-based biopharmaceutical company, focuses on therapies for liver and cardio-metabolic diseases, with its lead candidate, pegozafermin, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company went public on November 11, 2019, and employs 70 people.
89bio (ETNB) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, 89bio's actual EPS was -$1.02, missing the estimate of -$0.79 per share, resulting in a -29.62% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
